Efficacy of second-line targeted agents in kras wild metastatic colorectal cancer patients who received prior targeted agent: First anti-epidermal growth factor receptor or vascular endothelial growth factor in right and left colon?
Restricted accessResearch articleFirst published online June, 2020
Efficacy of second-line targeted agents in kras wild metastatic colorectal cancer patients who received prior targeted agent: First anti-epidermal growth factor receptor or vascular endothelial growth factor in right and left colon?
We aimed to investigate the impact of first biological agents on second-line biological agents in kras wild-type metastatic colon patients in right and left colon.
Patients and methods
The patients received anti-EGFR compared with anti-VEGF in right and left colon separately according to progression-free survival and overall survival in second line.
Results
A total of 84 patients were included in the study. In left colon, progression-free survival and overall survival were 9 and 14 months for anti-EGFR and 9 and 16 months for anti-VEGF in the second line. In right colon, progression-free survival and overall survival were 5 and 9 months for anti-EGFR and 4 and 6 months for anti-VEGF in the second line.
Conclusions
Progression-free survival was higher in patients who received bevacizumab first followed by anti-EGFR than reverse sequencing in right colon. Overall survival was similar between two groups.
JemalATiwariRCMurrayT, et al.Cancer statistics. CA Cancer J Clin2004; 54: 8–29.
2.
Van CutsemEKohneCHHitreE, et al.Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med2009; 360(14): 1408–1417.
3.
LetoSMTrusolinoL. Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. J Mol Med2014; 92(7): 709–722.
4.
BensonABBekaii-SaabTChanE, et al.Metastatic colon cancer, version 3. 2013: featured updates to the NCCN Guidelines. J Natl Compr Cancer Netw2013; 11(2): 141–152. quiz 152.
5.
De RoockWPiessevauxHDe SchutterJ, et al.KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol2008; 19: 508–515.
6.
GreystokeAMullamithaSA. How many diseases are colorectal cancer?. Gastroenterol Res Pract2012; 2012: 564741.
7.
BenedixFKubeRMeyerF, et al.Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum2010; 53: 57–64.
8.
BufillJA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med1990; 113: 779–788.
9.
MikMBerutMDzikiL, et al.Right- and left-sided colon cancer – clinical and pathological differences of the disease entity in one organ. Arch Med Sci2017; 13(1): 157–162.
10.
TejparSStintzingSCiardielloF, et al.Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol2016; 3(2): 194–201.
11.
HolchJWRicardIStintzingS, et al.The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer2017; 70: 87–98.
12.
TaberneroJ. The role of VEGF and EGFR Inhibition: Implications for combining antiVEGF and antiEGFR agents. Mol Cancer Res2007; 5(3): 203–220.
13.
CitriAYardenY. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol2006; 7: 505–516.
14.
SeshacharyuluPPonnusamyMPHaridasD, et al.Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Target2012; 16(1): 15–31.
15.
CouraTNehar-BelaidDFlorezL, et al.TGF-β and VEGF cooperatively control the immuno tolerant tumor environment and the efficacy of cancer immunotherapies. JCI Insight2016; 1(9): e85974.
16.
Lo NigroCRicciVVivenzaD, et al.Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy. World J Gastroenterol2016; 22: 6944–6954.
17.
GoldsteinNSArminM. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on cancer stage IV colon adenocarcinoma. Cancer2001; 92: 1331–1346.
18.
ZaniboniAFormicaV. The best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside. Cancer Chemother Pharmacol2016; 78: 233–244.
19.
QiuTChenWLiP, et al.Subsequent anti-VEGF therapy after first-line anti-EGFR therapy improved overall survival of patients with metastatic colorectal cancer. OncoTarget Ther2018; 11: 465–471.
20.
ZengMKikuchiHPinoMS, et al.Hypoxia activates the K-ras protooncogene to stimulate angiogenesis and inhibit apoptosis in colon cancer cells. PLoS One2010; 5(6): e10966.
21.
DerangèreVFumetJDBoidotR, et al.Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?. Oncotarget2016; 7: 9309–9321.
22.
HeskampSBoermanOCMolkenboer-KuenenJDM, et al.Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies. Int J Cancer2013; 133: 307–315.
23.
Valderrama-TreviñoAIBarrera-MeraBCeballos-VillalvaJC, et al.Montalvo-Javé hepatic metastasis from colorectal cancer. Euroasian J Hepatogastroenterol2017; 7(2): 166–175.
24.
HegdePSJubbAMChenD, et al.Predictive ımpact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab. Clin Cancer Res2013; 19(4): 929–937.
25.
SobreroAFMaurelJFehrenbacherL, et al.EPIC: phase III trial of cetuximab plus İrinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol2008; 26(14): 2311–2319.
26.
SeymourMTBrownSRMiddletonG, et al.Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol2013; 14(8): 749–759.
27.
PeetersMPriceTJCervantesA, et al.Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol2014; 25(1): 107–116.
28.
GiantonioBJCatalanoPJMeropolNJ, et al.Bevacizumab in combination with oxaliplatin fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the eastern cooperative oncology group study E3200. J Clin Oncol2007; 25(12): 1539–1544.
29.
FricPSovovaVSloncovaE, et al.Different expression of some molecular markers in sporadic cancer of the left and right colon. Eur J Cancer Prev2000; 9: 265–268.
30.
ModestDPStintzingSvon WeikersthalLF, et al.Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306). Oncotarget2017; 8(62): 105749–105760.
